Intravacc, a Netherlands-based company that deals with translational research and development of preventive and therapeutic vaccines, announced on Wednesday that that it has received a contract from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG).
The deal includes base and options that are likely to total USD14.6m.
The company is developing a prophylactic vaccine based on its proprietary outer membrane vesicles (OMV) platform technology. The NG vaccine is called NGoXIM and is based on gonococcal OMVs integrated with sustained-release microspheres containing recombinant human IL-12, and will be dosed intranasally.
Intravacc is developing a complete production process for NGoXIM to generate vaccine batches under Good Manufacturing Practices.
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Alvotech reports positive topline results for Xolair biosimilar study
DBV Technologies secures up to USD306.9m to advance Viaskin peanut patch programme
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial
CBC Group acquires UCB's mature neurology and allergy business in China